Skip to content
OpenCapital
Get started

Evommune EVMN Recognition Of Series C Convertible Notes

Other financials

Income statement

See full
Revenue$1.6M+3.5%
Gross profit$961.1K+10.9%
Operating income-$682.8K-2,027%
Net income-$7.0M-5,414%
EPS (diluted)-$0.36-1,700%

Balance sheet

See full
Cash & equivalents$1.1M+401%
Total debt$2.0M—
Total equity-$4.5M-3,048%
Total assets$7.2M—

Cash flow

See full
Operating cash flow-$424.6K-341%
CapEx$1.0-99.8%
Free cash flow-$2.7M-4,996%

Valuation

See full
Market cap$848.59M+39.5%
Enterprise value$849.52M—
P/S127.3×—

Profitability

See full
Gross margin53.7%—
Operating margin-30.7%—
Net margin-90.1%—

Returns & leverage

See full
Return on equity275.7%—
Debt / equity1.4×—
Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept meha:RecognitionOfSeriesCConvertibleNotes.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's recognition of series c convertible notes.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evommune 's recognition of series c convertible notes?
Evommune (EVMN) reported recognition of series c convertible notes of -$837K in Q1 2026.